back to

Back to video list

Early unfavorable: new standard of care?

Speaker

John Raemaekers

Session

Others Talks of this Session

Early favorable HL: pros and cons of PET-adapted therapy
NLPHL
Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial
Proton radiotherapy for mediastinal Hodgkin Lymphoma: single institution experience
Results of US intergroup trial of response-adapted chemotherapy or chemotherapy / radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB / Alliance 50604)